cyrilzakka/clinical-trials huggingface dataset:
The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.


Eligibility Criteria:
Inclusion Criteria:

* Within 48 hours of intensive care admission
* Evidence of suspected or confirmed infection
* Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
* Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min
* Lactate \>2mmol/L at any stage prior to randomisation

Exclusion Criteria:

* Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II
* Patients receiving other vasoactive drugs in addition to norepinephrine
* Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min)
* Patients receiving extra corporal membrane oxygenation (ECMO)
* Patients with acute occlusive coronary syndromes requiring intervention
* Patients with mesenteric ischaemia
* Patients with a history or presence of aortic dissection or abdominal aortic aneurysm
* Patients with Raynaud's syndrome or acute vaso-occlusive conditions
* Pregnancy
A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)

The purpose of this study is to evaluate the relationship between upper and lower airway allergen-induced cytokine responses in mild asthmatics by attempting to demonstrate the following: 1) a positive correlation between allergen-induced Type 2 T-helper cell (Th2) cytokines (interleukins 5 and 13) in sputum and nasal exudates; and 2) a positive correlation between effects of prednisone versus placebo on Th2 cytokines in sputum and nasal exudates.


Eligibility Criteria:
Inclusion Criteria:

* Has a clinical history of mild to moderate asthma for at least 6 months, but otherwise is in good health
* Participant with allergic rhinitis and asthma has a history of nonseasonal airway symptoms in response to aeroallergens OR has seasonal symptoms but can be evaluated out-of-season
* Is clinically stable and free of respiratory infection or change in allergen exposure for at least 4 weeks prior to start of study

Exclusion Criteria:

* Has intolerance to the study drug, inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication
* Has intolerance to lidocaine/lignocaine, sedatives, atropine or glycopyrrolate, or any other medication associated with bronchoscopy
* Has taken oral parenteral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 5 weeks of screening and/or during the study
* Has recent (4 weeks) or ongoing upper or lower respiratory tract infection
* Has active allergic rhinitis at screening
* Has received a vaccination within 3 weeks of screening
A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

Post-operative delirium is a common and deleterious complication in elderly patients. The investigators have previously found lower levels of serum tryptophan in post-operative elderly patients who developed delirium in comparison to post-operative elderly patients who did not develop delirium. The investigators hypothesize that post-operative supplementation of L-tryptophan will reduce the duration and incidence of post-operative delirium. This study is a double-blinded placebo controlled trial of L-tryptophan supplementation in post-operative ICU patients 60 years and older. The primary outcome measure is the comparison of duration of post-operative delirium in subjects who receive L-tryptophan supplementation versus a similar appearing control.

The sudy will compare rates and duration of postoperative delirium in groups that receive L-tryptophan supplementation compared to placebo.

Eligibility Criteria:
Inclusion Criteria:

* Included subjects will be 60 years and older undergoing an operation with a planned ICU admission post-operatively.

Exclusion Criteria:

* Medications that, when combined with tryptophan, increase the risk of serotonin syndrome. The classes of medications include:

  * monoamine oxidase inhibitors
  * selective serotonin reuptake inhibitors
  * serotonin-norepinephrine reuptake inhibitors
  * triptans
  * opioids
  * central nervous system stimulants
  * bupropion
  * St. John's Wort
* Patients who undergo an operation on their brain.
* Factors which prevent delirium assessment with the CAM-ICU: vision impairment or non-fluent English speakers.
* A lowered seizure threshold including:

  * history of seizure disorder
  * alcohol abuse defined by a high AUDIT score (\>8 females and \>13 males)
  * benzodiazepine or barbiturate abuse within three months of the study
  * OR a positive urine toxicology screen for alcohol, benzodiazepines or barbiturates.
* Significant liver disease (Child's class B or greater) or significant renal disease (Creatinine ≥2.0).
* History of Huntington's or Addison's disease. (As requested by the FDA)
* History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia). (As requested by the FDA)
* Women who are not post-menopausal. (As requested by the FDA)
Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)

Lacunar infarction is an ischemic stroke occurred by small perforating artery occlusion . Twenty percent of ischemic stroke is lacunar infarction.

However, outcome of lacunar infarction is excellent, about 20-40% patients are suffered neurological worsening.

Progressive lacunar infarction is associated poor functional outcome and neurological deficit.

Currently, no treatment for progressive lacunar infarction is recommended on the guideline.

Several small study reported that phenylephrine and magnesium may be helpful for progressive lacunar infarction.

Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.

CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.

Lacunar infarction is small and perfused with marginal flow by neighboring perforating arteriole.

Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressive lacunar infarction.

Induced hypertension is alternative treatment of progressive lacunar infarction. Increasing blood pressure also induce cerebral blood flow.

Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart.

Several studies reported that the effectiveness of phenylephrine on progressing stroke.

Therefore, this study will compare the effectiveness of carbogen versus phenylephrine in lacunar infarction patients who suffered neurological worsening.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥20 years
2. Anterior circulation progressive lacunar infarction.
3. Neurological worsening either 1 point in NIHSS score or MRC grade

Exclusion Criteria:

1. Age \<20
2. Cortical infarction
3. Posterior circulation lacunar infarction
4. Relevant artery stenosis more than 50% or occlusion
5. Moyamoya disease
6. Difficulty in inhalation of Carbogen (panic, severe anxiety disorder)
7. Drug allergy for phenylephrine
8. Persistent bradycardia (pulse rate \< 50 /min)
9. History of hemorrhagic stroke
10. Pre-stroke mRS ≥2
A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study

Primary

- To investigate the safety and tolerability of LCB01-0371 after a single oral dose

Secondary

* To investigate the pharmacokinetic characteristics of LCB01-0371 after a single oral dose
* To investigate the safety of LCB01-0371 after a single oral dose

* To investigate the pharmacokinetic characteristics of LCB01-0371 after a single oral dose
* To investigate the safety of LCB01-0371 after a single oral dose

Eligibility Criteria:
Inclusion Criteria:

1. Healthy Male between 20 and 45 years of age at the time of screening
2. Subjects with body mass index (BMI) between 20 and 27 at the time of screening
3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 30th days of study completion
4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements

Exclusion Criteria:

1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).
2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption within 6 months from screening
3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.
4. History of drug abuse or positive result at urine drug screening test
5. AST, ALT, r-GT, billirubin(total) values over than 1.5 times of ULN
Awareness Among Physiotherapists About Effectiveness of Sensory Integration Therapy on Cerebral Palsy Population.

The study is to interrogate the awareness level of physiotherapists that are working in the region of KHYBER PAKHTUNKHWA, to access whether they know about sensory integration therapy or they use it for the patients of cerebral palsy in their treatment plan or not.

The study title is ''AWARENESS AMONG PHYSICAL THERAPISTS OF KHYBER PAKHTUNKHWA ABOUT THE EFFECTIVENESS OF SENSORY INTEGRATION THERAPY ON CEREBRAL PALSY POPULATION.' it is a cross-sectional study that will be conducted in the province of Khyber Pakhtunkhwa, Pakistan. The data will be conducted by 110 physical therapists on a self designed tool, that will allow us to know about the awareness among the physical therapist of this particular region to know if they are using sensory integration therapy in the treatment plan of the children suffering from cerebral palsy to know whether the sensory issues are being addressed over there by this therapy or not. Another purpose of this study is to make the therapists aware about sensory integration therapy and its efficacy in treating sensory processing and sensory integration issues present in the children that are suffering from cerebral palsy. The data will be collected by the physical therapists that are currently working in various hospitals of Khyber Pakhtunkhwa located in different regions of the province.

Eligibility Criteria:
Inclusion Criteria:

* Physical Therapists working across Khyber Pakhtunkhwa representative of all divisions of the province.
* Physical Therapists working as clinicians or working in healthcare vicinities from at least 2 years.

Exclusion Criteria:

* Non practicing Physical Therapists
* Freshly graduated Physical Therapists
* Physical Therapists working in areas other than Khyber Pakhtunkhwa
Comparative Effects of Backward Treadmill Walking and Lower Extremity Cross Training Among Stroke Patients

Stroke is one of the high rated neurological disorders, induced by disruption of brain's blood flow. Stroke can alter the level of consciousness, motor and cognitive skills, sensory perception and language; it all depends on the extent of injury and the region of brain that is affected. Even though all the rehabilitation given to the "stroke" patients, but still 25-30% of the survivors still have gait and balance problem and they require complete physical support before their discharge from the hospital. Backward treadmill walking has reported numerous benefits in improving balance, motor function and gait. Cross training is a technique which is applied to healthy limb of the individual to increase muscle strength and muscle activity.so the aim of this study is to find the effects of backward treadmill walking and lower extremity cross training on gross motor function and balance among stroke patients.

The study will be randomized clinical trials, Participants will be randomly allocated into two groups each group will have 13. This study will be conducted in Safi teaching Hospital Faisalabad. Group A will be treated with backward treadmill walking and group B will be treated with lower extremity cross training. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down. Outcome will be measured before and after giving treatment by using Tinetti performance oriented mobility assessment and lower extremity functional scale. The results will be calculated by using SPSS version 25. Frequencies and mean standard deviation will be measured, parametric and non-parametric tests will be applied


Eligibility Criteria:
Inclusion Criteria:

* Hemiplegic stroke patient diagnosed within last 6 months to 1 year
* Age 55 to 75 years
* Cognition score on Mini-mental state examination \> 24
* Able to independently walk 10 m without walking aids
* Able to understand instructions

Exclusion Criteria:

* Who will have visual or vestibular injury
* Patients having history of orthopedic surgery or having an orthopedic condition
* Who will have \>grade 2 on modified Ashworth Scale (MAS)
Comparison of the Effectiveness of an Adapted Physical Activity Program in a Dedicated Structure to a Self-program in Patients in Chronic Phase of a Stroke

This is a prospective, randomized, controlled, two parallel arms, single-blind pilot study. In this design, all included patients in the chronic phase of a stroke will receive both modes of physical activity.

This study includes patients over 18 years of age with spastic hemiparesis sequelae of a first unilateral hemispheric stroke older than 6 months and able to walk for 6 minutes. The non-inclusion criteria were the inability to walk without human assistance (with or without technical aids), the existence of cognitive disorders compromising informed consent, in particular the inability to understand the objective and the modalities of the protocol, the inability to communicate with the examiners, and the presence of an additional neurological disorder or a pathology contraindicating the practice of physical activity.

The primary endpoint is based on daily activity measurement by measuring the number of steps per day, collected over the duration of the study, via a Stepwatch™ device. Secondary end points involve a written physical activity report, assessment of walking ability (via walking-test 6, heart rate, and blood pressure), a measure of perceived exertion, stroke-specific quality of life, balance, and motivation to perform physical activity.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 years
* Left or right spastic hemiparesis after a first hemorrhagic or ischemic unilateral stroke older than 6 months
* Walking possible for 6 minutes

Exclusion Criteria:

* Inability to walk without human assistance (with or without technical aids)
* Cognitive impairment that compromises informed consent, including inability to understand the purpose and terms of the protocol
* Inability to communicate
* Presence of an additional neurological disorder
* Medical conditions that contraindicate physical activity, such as an unbalanced cardiovascular or respiratory condition
* Concurrent participation in another clinical research project
Acute Vascular Response To Meals Varying In Glycemic Index And Glycemic Load

This study examines the effects of carbohydrate type (high- or low-Glycemic Index (GI)) and amount (high- or low-Glycemic Load (GL)) have on blood glucose levels, blood pressure and arterial stiffness in healthy individuals. It will also determine whether subjective ratings such as test meal palatability and hunger are related to changes in blood glucose. The investigators hypothesize that: (1) High-GI meals, regardless of GL, will increase arterial stiffness; low-GI meals, regardless of GL, will have a neutral or lowering effect on arterial stiffness (augmentation index). (2) High-GI meals, regardless of GL, will have an elevating effect on both central and peripheral blood pressures. (3) The incremental area under the curve for blood glucose will show most significant differences between high-GI, high-GL and low-GI, low-GL meals at 30 and 90 min.


Eligibility Criteria:
Inclusion Criteria:

* healthy
* age 18 - 75 years
* BMI 18 - 25 kg/m2
* brachial systolic blood pressure \< 140 mmHg
* brachial diastolic blood pressure \< 90 mmHg

Exclusion Criteria:

* primary hypertension
* diabetes
* allergy or sensitivity to any foods to be used in the study
* gastrointestinal disorders
* chronic kidney disease
* liver disease
* hepatitis
* estrogen-sensitive cancer
* heavy alcohol use
* sleep apnea
* bleeding disorders
* planned surgery (within time frame of study)
* angina
* Congestive Heart Failure
* coronary revascularization
* peripheral vascular disease and/or coronary/cerebrovascular events within the previous 6 months
* positive HIV diagnosis
* prescription of anti-depressants, anti-hypertensives, anti-coagulant medications, diuretics, sympathomimetics, herbal therapies, vitamin or K supplementation, medication affecting NO synthesis
* chronic use or prescription of NSAIDs
* women of childbearing potential must not be pregnant or breastfeeding
Treatment of Subclinical Hyperthyroidism

Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Randomized open-labelled multicentre study comparing radioiodine vs medical supervision without treatment

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged 50 and greater
* Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

Exclusion Criteria:

* Iodide overload
* Non sinusal heart rhythm
* Severe heart disease
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a 18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).

Eligibility Criteria:
Inclusion Criteria:

1. Histologically and/or clinically confirmed and/or suspicious of NEN.
2. Signed informed consent.

Exclusion Criteria:

1. Claustrophobia (unable to accept PET/CT scanning)
2. Pregnant or breast-feeding
Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder

The goal of this study is to identify the platelet defect responsible for the bleeding in families from our inherited platelet disorders Israeli-Palestinian registry. The investigators plan to characterize platelet proteome expression after removing high abundance proteins. The investigators will compare the proteome of sick and healthy members of families with inherited platelet disorders, and identify and validate structural proteins, signaling cascades and biomarkers for detection and diagnosis of unknown platelet disorders. The investigators expect to discover new key findings that allow better understanding of human platelet function and allow better diagnosis and treatment of patients with inherited platelet function disorders.


Eligibility Criteria:
Inclusion Criteria:

* History of inherited platelet disorders in the family

Exclusion Criteria:

* none
Anatomic and Clinical Long-term Follow-up of Conservatively Treated Rotator Cuff Tears

Study population: Patients who have been treated with physiotherapy for a potentially repairable rotator cuff tear in the period from 2002 to 2005.

Study Method: At the time of diagnosis (2002 to 2005) all study patients were examined clinically, sonographically and by MRI. Some patients also completed a shoulder score. All study patients will now be reexamined, 8 to 10 years after they were diagnosed. Reexamination includes history taking, clinical examination, completion of three shoulder scores (two shoulder specific scores, one general health score), Sonography and MRI. Findings of interest are

* the number of relapses during follow-up,
* the need for surgical treatment during follow-up,
* the deterioration of tear anatomy (tear size, muscle atrophy, fatty degeneration) during follow-up
* the actual clinical shoulder condition (as given by shoulder scores) at reexamination.

Study purpose: We want to assess the anatomic and clinical long-term results of physiotherapy for potentially repairable rotator cuff tears. We want to find out if tear anatomy of unrepaired rotator cuff tears deteriorates over time and if such a deterioration is associated with a development of more serious degrees of symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Full-thickness rotator cuff tear diagnosed between 2002 and 2005 by both sonography and MRI.

At the time of diagnosis (2002 to 2005):

* Typical clinical symptoms for a rotator cuff tear including pain laterally on upper humerus, painful arc, positive impingement test (Neer or Hawkins)
* Potentially repairable tear (tear size up to 3 cm, muscle atrophy not exceeding grade 2 according to Thomazeau, fatty degeneration not exceeding grade 1 according to Goutallier).
* Treated by physiotherapy for at least 3 months

Exclusion Criteria:

At the time of diagnosis (2002 to 2005):

* Full-thickness tears of the subscapularis tendon or of the entire supraspinatus and infraspinatus tendons
* Other symptomatic shoulder pathology including long head of the biceps tendon pathology, acromioclavicular joint pathology, shoulder instability, inflammatory diseases, glenohumeral arthritis
* Earlier treated with rotator cuff repair in the study shoulder